CodaVax-H1N1 for seasonal influenza
The Codagenix influenza vaccine, CodaVax-H1N1, was constructed using Codagenix’s proprietary, software-based algorithm to “de-optimize” the influenza HA and NA gene segments for reduced translation in human cells, thereby decreasing the virus’s ability to spread and grow. Preliminary data from Phase I clinical trials show that the vaccine is as safe as placebo and generates an immune response against influenza viruses from multiple seasons and multiple decades (e.g. influenza viruses from 1970s and 1930s). CodaVax has an open an IND from the FDA.
2017-2018 Influenza Season
Flu cases in 2017-18
Current vaccine <37% effective
deaths from influenza
Influenza vaccines have been plagued by low efficacy and short supply during outbreaks. CodaVax-H1N1 is positioned to be the first scalable, safe, and highly effective universal influenza vaccine. Unlike other live-attenuated influenza vaccines, CodaVax-H1N1 generates a broad robust immune response and does not rely on chicken eggs for production. CodaVax-H1N1 is grown in cell culture, which allows Codagenix to rapidly scale up production of the vaccine during an outbreak.